Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: Results from the optimization of adalimumab trial

Journal of Rheumatology

Volumn 37, Issue 12, 2010, Pages 2469-2474

  Pease, Christopher ^a   Pope, Janet E ^a   Thorne, Carter ^d   Haraoui, Boulos Paul ^e   Truong, Don ^c   Bombardier, Claire ^c   Widdifield, Jessica ^c   Psaradellis, Eliofotisti ^f   Sampalis, John S ^g   Bonner, Ashley ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f JSS Medical Research   (Canada)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

Clinical trials; Registries; Rheumatoid arthritis; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; AUROTHIOMALATE; AZATHIOPRINE; C REACTIVE PROTEIN; CHLOROQUINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; ARTHRALGIA; ARTHROPATHY; ARTICLE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNDING; GEOGRAPHIC DISTRIBUTION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE BLIND PROCEDURE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; FEMALE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649723958     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.091447     Document Type: Article

References (37)

1. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848.
2. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
3. Van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomised trial. Lancet 2009;374:459-66.
4. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
5. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
6. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD study. Ann Rheum Dis 2009;68:789-96.
7. Keystone E, Heijde D, Mason D Jr, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
8. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
9. Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: Uptake of new therapies. Eur J Health Econ 2008;8 Suppl 2:S61-86.
10. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: A survey of practicing Canadian rheumatologists. J Rheumatol 2002;29:255-60.
11. Ministry of Health, Government of British Columbia. Limited Coverage Drugs - Adalimumab/ Etanercept/ Infliximab/ Abatacept/Rituximab. [Internet. Accessed July 2009.] Available from: http://www.health.gov.bc.ca/pharmacare/
12. Alberta Health and Wellness, Government of Alberta. Special Authorization Guidelines. [Internet. Accessed July 2009.] Available from: http://www.health.alberta.ca/AHCIP/drug-benefit-list.html
13. Ministry of Health, Government of Saskatchewan. Appendix A - Exception Drug Status program. [Internet. Accessed July 2009.] Available from: http://formulary.drugplan.health.gov.sk.ca
14. Manitoba Health, Government of Manitoba. Exceptional Drug Status Program. [Internet. Accessed July 2009.] Available from: http://www.manitoba.ca/health/ mdbif/index.html
15. Ministry of Health and Long-Term Care, Government of Ontario. Comparative Drug Index. [Internet. Accessed July 2009.] Available from: http://www.health.gov.on.ca/
16. Régie de l'assurance maladie du Québec. List of Medications. [Internet. Accessed July 2009.] Available from: http://www.ramq.gouv.qc.ca/en/regie/lois/liste-med.shtml
17. Department of Health, Government of New Brunswick. New Brunswick Prescription Drug Program Special Authorization Criteria. [Internet. Accessed July 2009.] Available from: http://www.gnb.ca/0051/0212/index-e.asp
18. Department of Social Services and Seniors, Government of Prince Edward Island. The Prince Edward Island Drug Programs Formulary. [Internet. Accessed July 2009.] Available from: http://www.gov.pe.ca/health
19. Department of Health, Government of Nova Scotia. Nova Scotia Formulary. [Internet. Accessed July 2009.] Available from: http://www.gov.ns.ca/health/ Pharmacare/formulary.asp
20. The Newfoundland and Labrador Prescription Drug Program, Department of Health and Community Services, Government of Newfoundland and Labrador. Criteria for the Coverage Of Special Authorization Drugs. [Internet. Accessed July 2009.] Available from: http://www.health.gov.nl.ca/health/nlpdp/sadsearch.asp
21. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2008;67:1023-6.
22. Kvien TK, Heiberg MS, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al. A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;5 Suppl 39:S188-94.
23. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish biologics register. Ann Rheum Dis 2009;68:648-53.
24. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008;67:37.
25. Hjardem E, Hetland ML, Ostergaard M, Krogh NS, Kvien TK, Danish Database for Biological Therapies in Rheumatology Study Group. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: Criteria are becoming less stringent. Ann Rheum Dis 2005;64:1220-3.
26. Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SM, Lund Hetland M, et al. QUEST-RA: Quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66:1491-6.
27. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: A population study. Arthritis Rheum 2005;53:241-8.
28. Haraoui B. Canadian Rheumatology Association position on the use of biologic agents for the treatment of rheumatoid arthritis. 2001. [Internet. Accessed July 21, 2010.] Available from: http://rheum.ca/Resources/Pdf/ Biologics-for-RA.pdf
29. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
30. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
31. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14. (Pubitemid 38996967)
32. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
33. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
34. St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
35. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 2006;33:2398-408.
36. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl 2:ii13-6.
37. DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 2006;166:57-63.